Are Biopharma Firms Discontinuing Doomed Drug Discovery Projects Fast Enough?

Abstract

Annapoornima M. Subramanian, Moren Lévesque, and Vareska Van De Vrande were recognized as a runner up for the 2020 Ralph Gomory Best Industry Studies Paper Award.

Keywords

time to discontinuation drug discovery time allocation decision biopharma industry Gomory award industry studies

Get full access to this article

View all access options for this article.

References

Deloitte Report . 2020. Ten Years on Measuring the Return from Pharmaceutical Innovation 2019. Available at https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life‐sciences‐health‐care/deloitte‐uk‐ten‐years‐on‐measuring‐return‐on‐pharma‐innovation‐report‐2019.pdf (accessed date May 18, 2021).

Kanapeckaite

2021. The Hidden Costs of Mismanaged R&D Projects in Biotech and Pharma. Available at https://www.labiotech.eu/opinion/mismanaged‐projects‐biotech‐pharma/ (accessed date November 2, 2021).

2017. Counting the Cost of Failure in Drug Development. Available at https://www.pharmaceutical‐technology.com/features/featurecounting‐the‐cost‐of‐failure‐in‐drug‐development‐5813046/ (accessed date November 2, 2021).

Luger

Raisch

Schimmer

. 2018. Dynamic balancing of exploration and exploitation: The contingent benefits of ambidexterity. Organ. Sci. 29(3): 449–470.